121 related articles for article (PubMed ID: 32157528)
21. STAT3-mediated MLST8 gene expression regulates cap-dependent translation in cancer cells.
Lee H; Chin H; Kim H; Jung H; Lee D
Mol Oncol; 2020 Aug; 14(8):1850-1867. PubMed ID: 32495998
[TBL] [Abstract][Full Text] [Related]
22. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
[TBL] [Abstract][Full Text] [Related]
23. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
24. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
25. Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway.
Wang F; Xu WQ; Zhang WQ; Xu RC; Sun JL; Zhang GC; Liu ZY; Qi ZR; Dong L; Weng SQ; Shen XZ; Liu TT; Fang Y; Zhu JM
Hepatol Int; 2024 Apr; 18(2):636-650. PubMed ID: 37982952
[TBL] [Abstract][Full Text] [Related]
26. miR-106b-5p promotes aggressive progression of hepatocellular carcinoma via targeting RUNX3.
Gu H; Gu S; Zhang X; Zhang S; Zhang D; Lin J; Hasengbayi S; Han W
Cancer Med; 2019 Nov; 8(15):6756-6767. PubMed ID: 31503422
[TBL] [Abstract][Full Text] [Related]
27. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
Li W; Fu Q; Man W; Guo H; Yang P
Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
[TBL] [Abstract][Full Text] [Related]
28. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.
Lu C; Ning Z; Wang A; Chen D; Liu X; Xia T; Tekcham DS; Wang W; Li T; Liu X; Liu J; Qi H; Luo H; Du J; Ma C; Yan Q; Liu J; Xu G; Piao HL; Tan G
Cancer Lett; 2018 Nov; 436():139-148. PubMed ID: 30056112
[TBL] [Abstract][Full Text] [Related]
29. A model prediction of long-term prognosis in patients with centrally located hepatocellular carcinoma undergoing hepatectomy.
Yantong Y; Shan L; Zhijie C; Youwei Z
Eur J Surg Oncol; 2018 Oct; 44(10):1595-1602. PubMed ID: 30041973
[TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
31. KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance.
Wang Y; Jiang J; Li Q; Ma H; Xu Z; Gao Y
Int J Clin Oncol; 2016 Oct; 21(5):927-933. PubMed ID: 27095111
[TBL] [Abstract][Full Text] [Related]
32. Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma.
Rao QW; Zhang SL; Guo MZ; Yuan FF; Sun JL; Qi F; Wang LS; Yang BW; Xia JL
Cancer Med; 2020 Nov; 9(22):8318-8332. PubMed ID: 32955798
[TBL] [Abstract][Full Text] [Related]
33. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
34. Nudix hydrolase 1 is a prognostic biomarker in hepatocellular carcinoma.
Ou Q; Ma N; Yu Z; Wang R; Hou Y; Wang Z; Chen F; Li W; Bi J; Ma J; Zhang L; Su Q; Huang X
Aging (Albany NY); 2020 Apr; 12(8):7363-7379. PubMed ID: 32341205
[TBL] [Abstract][Full Text] [Related]
35. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
37. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
38. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.
Liu Z; Dou C; Yao B; Xu M; Ding L; Wang Y; Jia Y; Li Q; Zhang H; Tu K; Song T; Liu Q
Oncotarget; 2016 Jun; 7(24):36909-36923. PubMed ID: 27191994
[TBL] [Abstract][Full Text] [Related]
39. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
